Sanolium publishes bond prospectus and applies for listing of its bonds on Nasdaq Stockholm

Sanolium AB (publ) (the "Company" or "Sanolium") has issued a senior secured bond loan of SEK 1,000,000,000 on 15 March 2024, within a total framework amount of SEK 1,500,000,000, on the Swedish bond market (the "Bonds"). The Bonds carry a floating interest rate of STIBOR 3m + 4.00 per cent. per annum and matures 15 March 2029.

The Company will apply for listing of the Bonds on the Corporate Bond list at Nasdaq Stockholm. The Bonds will be admitted to trading at Nasdaq Stockholm as soon as possible.

In connection with this, the Company has prepared a prospectus. The prospectus has been approved by, and registered with, the Swedish Financial Supervisory Authority in accordance with the Financial Instruments Trading Act (1991:980). The prospectus will be available on the Financial Supervisory Authority’s website (www.fi.se) and on the Company's website (https://www.cambio.se/om-oss/investor-relations/).

For further information, please contact:

Rami Avidan, CEO, Cambio
+46 070 793 483
rami.avidan@cambio.se

Johannes Fabó, CFO, Cambio
+46 730 599 368
Johannes.fabo@cambio.se

Jenny Styren, Chief Marketing & Communications Officer, Cambio
+46 703 793 483
jenny.styren@cambio.se

This information is information that Sanolium AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:00 CEST on 25 April 2024.

About the Company:

Sanolium AB, parent of the Cambio Group ("Cambio" or the "Company") operating entities, is an e-health company providing comprehensive IT solutions to improve healthcare and patient safety. Cambio is one of the largest suppliers in Scandinavia with more than 200,000 users across regions and municipalities, general and university hospitals, health centers and specialist units. Cambio has offices in Sweden, Denmark, United Kingdom and Sri Lanka.